CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 21,674	$ 8,953	$ 52,646	$ 20,704	$ 33,087
Cost of revenues	11,118	5,659	28,897	14,306	20,610
Impairment of field equipment			6,412
Gross profit	10,556	3,294	17,337	6,398	12,477
Operating costs and expenses:
Research, development and clinical trials	10,233	10,211	32,996	32,903	43,748
Sales and marketing	15,865	8,916	43,771	24,137	38,861
General and administrative	12,723	8,405	38,010	22,748	33,864
Total operating costs and expenses	38,821	27,532	114,777	79,788	116,473
Operating loss	(28,265)	(24,238)	(97,440)	(73,390)	(103,996)
Financial expenses, net	2,189	809	3,293	2,277	3,151
Loss before income tax expense	(30,454)	(25,047)	(100,733)	(75,667)	(107,147)
Income tax expense	3,174	976	8,944	2,986	4,434
Net loss	$ (33,628)	$ (26,023)	$ (109,677)	$ (78,653)	$ (111,581)
Basic and diluted net loss per ordinary share	$ (0.39)	$ (2.09)	$ (1.29)	$ (6.21)	$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	85,774,874	12,431,586	85,153,644	12,666,455	30,401,603